Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 4/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 4/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylephrine SCHEMBL4711 | 1.00 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29382851 | 1.00 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL4712 | 1.00 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29392606 | 1.00 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL29374674 | 1.00 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL24655 | 0.98 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL10953364 | 0.98 | HIF1A (0.96) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL21829033 | 0.98 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL412215 | 0.98 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 | |
| Phenylephrine SCHEMBL24654 | 0.98 | HIF1A (1.00) | HIF1AADRA2AADRA2BADRA2CADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455692-B2 | Process for resolution of 1-(3-hydroxyphenyl)-2-methylamino ethanol | Divi's Laboratories, Ltd. (IN) | 2013-06-04 | — | — | US | claimed |
| US-20120108848-A1 | PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL | DIVI'S LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | claimed |
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-04-16 | — | — | US | disclosed |
| CN-116410095-A | Synthesis method of phenylephrine hydrochloride | 凯特立斯（深圳）科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116410095-A | Synthesis method of phenylephrine hydrochloride | 凯特立斯（深圳）科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-115784907-A | Preparation method of DL-phenylephrine | 绪必迪药业(沧州)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-109576313-B | Method for preparing (S) -2-chloro-1- (3-hydroxyphenyl) ethanol | 尚科生物医药（上海）有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3095466-B1 | PHARMACEUTICAL FORMULATIONS WITH IMPROVED SOLUBILITY AND STABILITY | ABDI IBRAHIM ILAC SANAYI VE TICARET A S (TR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200085766-A1 | METHODS AND COMPOSITIONS OF STABLE PHENYLEPHRINE FORMULATIONS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2020-03-19 | — | — | US | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-20080014261-A1 | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction | EVERETT LABORATORIES, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007130429-A2 | HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7232837-B2 | Stereoisomers with high affinity for adrenergic receptors | MCNEIL-PPC, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232837-B2 | Stereoisomers with high affinity for adrenergic receptors | MCNEIL-PPC, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-6900203-B2 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | POLIUM TECHNOLOGIES, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-01 | — | — | US | disclosed |
| WO-1998051292-A1 | SYMPATHOMIMETIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-11-19 | — | — | WO | disclosed |
| US-4681940-A | ANTIALLERGENS, ANTIINFLAMMATORY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-21 | — | — | US | disclosed |
| EP-0226342-A1 | 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ADRA1A 725/4885ADRA1B 545/4885ADRA1D 231/4885 |
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | ACHE, ALKBH3, BCHE | ADRA1A 854/4885ADRA1B 581/4885ADRA1D 354/4885 |
| US-20200085766-A1 | METHODS AND COMPOSITIONS OF STABLE PHENYLEPHRINE FORMULATIONS | ADRA2C, ADRA1A, ADRB1 | ADRA1A 2/4885ADRA1B 6/4885ADRA1D 11/4885 |
| US-20120108848-A1 | PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL | ADH1A, CYP2E1, ADH1C | ADRA1A 187/4885ADRA1B 313/4885ADRA1D 271/4885 |
| US-11957646-B2 | Methods and compositions of stable phenylephrine formulations | ADRA2C, ADRA1A, ADRB1 | ADRA1A 2/4885ADRA1B 6/4885ADRA1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.